Technical Analysis for ABBV - AbbVie Inc.

Grade Last Price % Change $ Change
grade C $61.94 0.95% 0.58
ABBV closed up 0.95 percent on Thursday, February 23, 2017, on 1.16 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Flat Flat Up
See historical ABBV trend table...

Date Alert Name Type % Chg
Feb 23 Crossed Above 50 DMA Bullish 0.00%
Feb 23 Upside 200 DMA Break Bullish 0.00%
Feb 23 Spinning Top Other 0.00%
Feb 23 Bollinger Band Squeeze Range Contraction 0.00%
Feb 23 Upper Bollinger Band Walk Other 0.00%
Feb 22 Fell Below 50 DMA Bearish 0.95%
Feb 22 200 DMA Resistance Bearish 0.95%
Feb 22 Stochastic Sell Signal Bearish 0.95%
Feb 22 Bollinger Band Squeeze Range Contraction 0.95%
Feb 22 Upper Bollinger Band Walk Other 0.95%

Older signals for ABBV ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.

Profile
AbbVie Inc., a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. Its product portfolio includes a range of adult and pediatric pharmaceuticals, including HUMIRA, a biologic therapy administered as a subcutaneous injection to treat various autoimmune diseases; Synthroid used in the treatment of hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, as well as to increase HDL cholesterol levels; Synagis, which protects at-risk infants from severe respiratory disease or respiratory syncytial virus; Sevoflurane, an anesthesia product for human use; Duodopa, a levodopa-carbidopa intestinal gel used to treat advanced Parkinson's disease; and Zemplar used for the prevention and treatment of secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has collaboration with Alvine Pharmaceuticals, Inc. to develop a oral treatment for patients with celiac disease. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois. As of January 01, 2013.AbbVie Inc. operates independently of Abbott Laboratories.
Is ABBV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 0 bearish and 5 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 67.5
52 Week Low 52.76
Average Volume 6,927,400
200-Day Moving Average 61.93
50-Day Moving Average 61.69
20-Day Moving Average 60.98
10-Day Moving Average 61.26
Average True Range 0.92
ADX 13.23
+DI 17.1
-DI: 16.47
Chandelier Exit (Long, 3 ATRs) 59.48
Chandelier Exit (Short, 3 ATRs) 62.03
Upper Bollinger Band 62.04
Lower Bollinger Band 59.92
Percent B (%b) 0.95
Bandwidth 0.034765